Act now! Join the Carvykti® email writing campaign
Earlier this fall, national negotiations to secure public reimbursement for Carvykti® were terminated without agreement.
Without public funding, many patients face no option but continued, repeated therapies—each with their own risks, side effects, and costs.
Provincial and territorial decisionmakers must restart negotiations with the manufacturer and make Carvykti publicly accessible to all Canadians.
Tell your provincial/territorial representatives to restart Carvykti® negotiations and make patients the priority.
| 
